Background Bedaquiline and delamanid are the first drugs of new classes registered for
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …

Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a
global public health threat. A significant challenge for TB control efforts has been the …

Background There is a need for short and safe all-oral treatment of rifampicin-resistant
tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients …

The World Health Organization (WHO) recommends that countries implement
pharmacovigilance and collect information on active drug safety monitoring (aDSM) and …

Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …

Rationale Bedaquiline has been classified as a group A drug for the treatment of multidrug-
resistant tuberculosis (MDR-TB) by the World Health Organization; however, globally …

The World Health Organization's End TB Strategy prioritizes universal access to an early
diagnosis and comprehensive drug susceptibility testing (DST) for all individuals with …

Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-
based methods being considered the gold standard for drug susceptibility testing, molecular …

Summary The Lancet Respiratory Medicine Commission on drug-resistant tuberculosis was
published in 2017, which comprehensively reviewed and provided recommendations on …

Drug-resistant tuberculosis (TB) is estimated to cause 13% of all antimicrobial resistance-
attributable deaths worldwide and is driven by both ongoing resistance acquisition and …